Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancerJesús García-Foncillas, Josep Tabernero, Elena Élez, et al.
Cell Cycle (Georgetown, Tex.)|September 25, 2007
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicinMaria A Tapia, Irene González-Navarrete, Alba Dalmases, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 5, 2024
New Approach in the Interpretation of Complex Triple-negative Breast Cancer Immunohistochemistry Specimens Processed With VENTANA PD-L1 (SP142) AssayVicente Peg, Marta Abengozar-Muela, Jesús Acosta, et al.
Scientific Reports|July 14, 2021
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancerNatalia Palazón-Carrión, Carlos Jiménez-Cortegana, M Luisa Sánchez-León, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 19, 2013
Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathwayFederico Rojo, Laia Domingo, Maria Sala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancerGunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
Exercise Immunology Review|June 26, 2023
Combined exercise intervention in a mouse model of high-risk neuroblastoma: effects on physical, immune, tumor and clinical outcomesCecilia Rincón-Castanedo, Asunción Martín-Ruiz, Sandra Zazo, et al.
The Journal of Clinical Investigation|August 30, 2008
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerArkaitz Carracedo, Li Ma, Julie Teruya-Feldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2018
NK Cell Infiltrates and HLA Class I Expression in Primary HER2<sup>+</sup> Breast Cancer Predict and Uncouple Pathological Response and Disease-free SurvivalAura Muntasell, Federico Rojo, Sonia Servitja, et al.
Pageof 23